Diligence memo · auto-generated · as of July 2, 2026
Cleveland Diagnostics, Inc.
Cleveland Diagnostics, Inc. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
Cleveland Diagnostics, Inc. operates in Biotechnology, based in CLEVELAND.
Sub-sector tags: medical-devices.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Cleveland Diagnostics, Inc. has raised $73M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $56M on 2024-01-16.
Most recent recorded round closed around 2025-10-07.
Valuation (modeled)modeled
Provath models Cleveland Diagnostics, Inc. at approximately $79M (range $45M–$101M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.41× the median modeled value of Series C Biotechnology companies in 2025–2027 (58 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 42 months.
Last raise 9 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 3.9× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 87% of Biotechnology peers (4293 compared).
Modeled value ranks above 54% of those peers.
Closest niche peers: Newleos Therapeutics, Inc., Biolinq Inc, Atsena Therapeutics, Inc., Galvanize Therapeutics, Inc., X4 Pharmaceuticals, Inc.
Peoplefiled
12 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.